Search results for "ascites"

showing 10 items of 94 documents

Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.

2021

Background & Aims Transjugular intrahepatic portosystemic shunt (TIPS) implantation is an effective and safe treatment for complications of portal hypertension. Survival prediction is important in these patients as they constitute a high-risk population. Therefore, the aim of our study was to develop an alternative prognostic model for accurate survival prediction after planned TIPS implantation. Methods A total of 1,871 patients with de novo TIPS implantation for ascites or secondary prophylaxis of variceal bleeding were recruited retrospectively. The study cohort was divided into a training set (80% of study patients; n = 1,496) and a validation set (20% of study patients; n = 375). Furth…

0301 basic medicineLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPopulationClinical Decision-MakingSerum Albumin HumanEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAscitesmedicineSecondary PreventionHumanseducationAgedRetrospective Studieseducation.field_of_studyFramingham Risk ScoreHepatologyProportional hazards modelbusiness.industryAge FactorsAscitesBilirubinMiddle Agedmedicine.diseasePrognosisSurvival Rate030104 developmental biologyTreatment OutcomeResearch DesignCreatinineCohortPortal hypertension030211 gastroenterology & hepatologyFemalemedicine.symptomPortasystemic Shunt Transjugular IntrahepaticbusinessGastrointestinal HemorrhageTransjugular intrahepatic portosystemic shuntJournal of hepatology
researchProduct

Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites.

2018

Till date, the utility of cytologic assessment of ascites for the identification of hepatocellular carcinoma (HCC) cells is still debated and the usefulness of immunocytochemistry for glypican-3 (GPC3) and Hep Par-1 in this setting has not been reported. Liquid-based cytology of ascitic fluid of 28 cirrhotic patients was performed and the spots obtained were stained with hematoxylin and eosin, papanicolau, and with GPC3 and Hep Par-1 antibodies. GPC3 and Hep Par-1 antibodies stained positively the atypical cells in the ascites of 2 patients with HCC showing an exophytic growth pattern. The specimens of the patients with nonexophytic HCC, other non-HCC cancers, or cirrhosis stained negativel…

0301 basic medicinePathologymedicine.medical_specialtyHistologyCirrhosisCarcinoma HepatocellularH&E stainneoplastic asciteGlypican 3EpitheliumPathology and Forensic Medicineperitoneal effusionDiagnosis Differential03 medical and health sciencesimmunocytochemistry0302 clinical medicineGlypicansCytologyAscitesCarcinomaMedicineHumansProspective StudiesHCCneoplasmsReceptors Eph Familybusiness.industryLiver NeoplasmsAsciteshepatocellular carcinomamedicine.diseaseFibrosisImmunohistochemistryglypican-3digestive system diseasesMedical Laboratory Technology030104 developmental biologyLiver030220 oncology & carcinogenesisHepatocellular carcinomaImmunohistochemistrymedicine.symptomHep Par-1businessApplied immunohistochemistrymolecular morphology : AIMM
researchProduct

Add-On Peginterferon Alfa-2a Significantly Reduces HBsAg Levels in HBeAg-Negative, Genotype D Chronic Hepatitis B Patients Fully Suppressed on Nucleo…

2016

23 (36%) cases, respectively. Ribavirin (RBV) was used in 35% and 65% of the patients receiving SOF and DCV, respectively. Most of the patients were male (72%) and genotype 1b (81%). Median age was 59 years. Median baseline MELD and Child–Pugh (CPT) scores were 9 and 6, respectively. Among the patients with cirrhosis, 47% were CPT B/C. Tacrolimus was the immunosuppressant used in the majority of the patients (69%). At the beginning of therapy, 20 patients had ascites and 3 had hepatic encephalopathy (HE). Thirty-four patients completed the treatment course and 30 are still on therapy. End of treatment (EOT) response was 88% (30/34) and SVR12 was 83% (25/30). In patients receiving SMV+DCV±RB…

0301 basic medicinemedicine.medical_specialtyHBsAgCirrhosisAnemiaGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAscitesmedicineHepatic encephalopathyHepatologybusiness.industryRibavirinmedicine.disease030104 developmental biologychemistryImmunology030211 gastroenterology & hepatologyLiver functionmedicine.symptombusinessPeginterferon alfa-2amedicine.drugJournal of Hepatology
researchProduct

Case Report: Primary Peritonitis as the Onset of Pediatric Ménétriers Disease

2021

Introduction: Primary peritonitis (PP) and Ménétrier's Disease (MD) are both rare conditions among pediatric population. Although about 150 MD cases have been described in the scientific literature to date, its onset with a PP is an unusual condition.Case Presentation: We present a case of an 11-year-old boy who was admitted to our unit because of abdominal pain and distension. Complementary tests showed ascites, bilateral pleural effusion, leukocytosis, increased acute phase reactants and hypoproteinemia with hypoalbuminemia. Laparoscopy ruled out appendicitis or visceral perforations and exposed purulent peritoneal fluid, compatible with PP. Biochemical stool analysis showed increased cle…

Abdominal painmedicine.medical_specialtyPediatricsGastroenterology03 medical and health sciencesHypoproteinemia0302 clinical medicine030225 pediatricsInternal medicineMénétrier's diseaseAscitesmedicinecase reportEnteropathyHypoalbuminemiaprotein-losing enteropathybusiness.industryProtein losing enteropathylcsh:RJ1-570lcsh:Pediatricsmedicine.diseaseAppendicitisMénétrier's diseasehypertrophic gastropathyPediatrics Perinatology and Child Health030211 gastroenterology & hepatologymedicine.symptombusinessprimary peritonitisFrontiers in Pediatrics
researchProduct

Pattern of macrovascular invasion in hepatocellular carcinoma

2021

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed …

Ablation TechniquesMaleRegistrieCirrhosisClinical BiochemistryMesenteric Veinloco-regional treatment030204 cardiovascular system & hematologyBiochemistryGastroenterologysurgeryAntineoplastic AgentLiver disease0302 clinical medicineNon-alcoholic Fatty Liver Diseasecirrhosis; hepatocellular carcinoma; loco-regional treatment; portal vein thrombosis; surgery; transplantationAscitesAblation Techniqueportal vein thrombosisRegistries030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaPortal VeinLiver DiseasesLiver NeoplasmsAsciteshepatocellular carcinomaGeneral MedicineMiddle AgedSorafenibPrognosisHepatitis BAlcoholicHepatitis CTumor BurdenSurvival RateItalyLiver NeoplasmHepatocellular carcinomaAsciteFemalemedicine.symptomLiver cancerHumanmedicine.medical_specialtyCarcinoma HepatocellularPrognosiAntineoplastic AgentsEnd Stage Liver Disease03 medical and health sciencesMesenteric VeinsHepatitis B ChronicInternal medicinemedicineHumansHepatectomyNeoplasm Invasivenessportal vein thrombosiLiver Diseases AlcoholicAgedNeoplasm Invasivene...Performance statusbusiness.industrycirrhosisCarcinomaSettore MED/09 - MEDICINA INTERNAPatient AcuityHepatocellularHepatitis C Chronicmedicine.diseaseLiver TransplantationTransplantationLiver functionbusinesscirrhositransplantationEuropean Journal of Clinical Investigation
researchProduct

Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis.

2008

We tested the hypothesis that the presence of bacterial DNA (bactDNA) in ascitic fluid and serum is associated with decreased survival in patients with cirrhosis. In a prospective, multicenter study, we analyzed the clinical evolution of 156 patients with cirrhosis and ascites (first or recurrence) with lower than 250 polymorphonuclear cells (PMN)/L, negative ascites bacteriological culture, and absence of other bacterial infections being admitted for evaluation of largevolume paracentesis, according to the presence of bactDNA at admission. Survival, causes of death, and successive hospital admissions were determined during a 12-month follow-up period. BactDNA was detected in 48 patients. T…

AdultDNA BacterialLiver CirrhosisMalemedicine.medical_specialtyCirrhosisNeutrophilsKaplan-Meier EstimatePeritonitisGastroenterologyLiver diseaseSpontaneous bacterial peritonitisRisk FactorsInternal medicineAscitesParacentesisEscherichia coliMedicineAscitic FluidHumansProspective StudiesProspective cohort studyCause of deathAgedAged 80 and overHepatologymedicine.diagnostic_testbusiness.industryIncidenceAscitesHepatologyMiddle Agedmedicine.diseasePrognosisSurgeryMultivariate AnalysisFemalemedicine.symptombusinessLiver FailureFollow-Up StudiesHepatology (Baltimore, Md.)
researchProduct

Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunc…

2015

Abstract Background Cirrhotic cardiomyopathy may lead to heart failure in stressful circumstances, such as after transjugular intrahepatic portosystemic shunt (TIPS) placement. Aim To examine whether acute volume expansion predicts haemodynamic changes after TIPS and elicits signs of impending heart failure. Methods We prospectively evaluated refractory ascites patients (group A) and compensated cirrhotics (group B), who underwent echocardiography, NT-proBNP measurement, and heart catheterization before and after volume load; group A repeated measurements after TIPS. Results 15 patients in group A (80% male; 54 ± 12.4 years) and 8 in group B (100% male; 56 ± 6.2 years) were enrolled. Echoca…

AdultLiver CirrhosisMaleCardiac Catheterizationmedicine.medical_specialtymedicine.medical_treatmentCardiac indexDiastoleElectrocardiographyInternal medicineNatriuretic Peptide BrainmedicineHumansProspective StudiesPulmonary wedge pressureAgedCardiac catheterizationHeart Failure DiastolicHepatologybusiness.industryHemodynamicsGastroenterologyAscitesMiddle Agedmedicine.diseasePeptide Fragmentsmedicine.anatomical_structureEchocardiographySpainHeart failureHeart catheterizationVascular resistanceCardiologyFemaleVascular ResistancePortasystemic Shunt Transjugular IntrahepaticbusinessTransjugular intrahepatic portosystemic shuntDigestive and Liver Disease
researchProduct

Inguinal hernioplasty in patients with cirrhosis and ascites: what preventive measures are needed for a safe procedure?

2019

Inguinal hernioplasty in patients with LC and ascites has been long discouraged for the incidence of postoperative complications. The aim is to evaluate the appropriateness of this elective surgical procedure in patients with LC and ascites.Thirty consecutive LC patients with ascites and affected by inguinal hernia (LC group), who underwent elective open inguinal hernioplasty with mesh placement, have been matched with the same number of patients non-LC (non-LC group) who underwent the same surgical procedure in the same period of time. All patients in LC group received a careful hepatological assessment and were classified according to the etiology of LC and to the Child's class. Patients …

AdultLiver CirrhosisMaleLiver CirrhosiAscitesHernia InguinalMiddle AgedPostoperative ComplicationsCase-Control StudiesAsciteHumansCase-Control StudieHerniorrhaphyHuman
researchProduct

Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.

2009

Summary Background  In patients with cirrhosis, ascites is defined as refractory when it cannot be mobilized or recurs early in standard diuretic therapy. Aim  To compare the safety and efficacy of intravenous high-dose furosemide + hypertonic saline solutions (HSS) with repeated paracentesis in patients with cirrhosis and refractory ascites. Patients and methods  Eighty-four subjects (59/25 M/F) with cirrhosis, mostly of viral aetiology, admitted for refractory ascites, were randomly assigned to receive furosemide (250–1000 mg/bid i.v.) plus HSS (150 mL H2O with NaCl 1.4–4.6% or 239–187 mEq/L) (60 patients, Group A) or to repeated paracentesis and a standard diuretic schedule (24 patients,…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPilot ProjectsRefractoryFurosemideAscitesmedicineParacentesishypertonic saline solutionHumansParacentesisPharmacology (medical)DiureticsAgedAged 80 and overSaline Solution HypertonicRCT; hypertonic saline solution; ascitesHepatologymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGastroenterologyFurosemideAscitesMiddle Agedmedicine.diseaseHypertonic salineSurgeryTreatment OutcomeEffusionAnesthesiaFemaleDiureticmedicine.symptombusinessRCTmedicine.drugAlimentary pharmacologytherapeutics
researchProduct

Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis.

2005

: Background: Cyclic GMP (cGMP) concentration is increased in plasma of patients with liver cirrhosis. Three possible mechanisms may contribute: increased cGMP synthesis by soluble (activated by nitric oxide), or particulate (activated by atrial natriuretic peptide (ANP)) guanylate cyclase or increased release from cells. Aim: The aim of this work was to analyze the possible contributors to increased plasma cGMP and to assess whether changes in the parameters of the system vary with the degree of liver disease (Child Pugh score) or by the presence of ascites. Methods: We measured cGMP in plasma and lymphocytes, soluble guanylate cyclase activation by nitric oxide in lymphocytes, nitrates an…

AdultLiver CirrhosisMalemedicine.medical_specialtyGUCY1B3Nitric OxideNitric oxidechemistry.chemical_compoundAtrial natriuretic peptideInternal medicinemedicineHumansLymphocytesCyclic GMPCells CulturedNitritesAgedNitratesHepatologyPenicillamineGUCY1A3AscitesMiddle AgedNPR1PDE5 drug designEndocrinologychemistryGuanylate CyclaseCGMP transportAtrial Natriuretic FactorHomeostasisLiver International
researchProduct